Hepatitis Drugs Market Size, Share, Outlook, and Opportunity Analysis, 2020– 2027

1. HEPATITIS DRUGS MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027 © Coherent market Insights. All Rights Reserved © Coherent market Insights. All Rights Reserved

2. REPORT DESCRIPTION Hepatitis Drugs Market - Overview Global Hepatitis Drugs Market, By Drug Class (Interferon Alphas, HIV NRTIs, Nucleotide Polymerase/NS5A Inhibitor Combinations, Hepatitis C Protease/NS5A Inhibitor Combinations, NS5A Inhibitors, Nucleotide Polymerase Inhibitors, Nucleoside Analogue Antivirals, and Thrombopoiesis Stimulating Agents), By Disease Type (Hepatitis B, Hepatitis C, and Others), By Route of Administration (Oral and injection), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 21,148.3 million in 2019, and is projected to exhibit a CAGR of 3.2% over the forecast period (2019 - 2027), as highlighted in a new report published by Coherent Market Insights. Increasing number of government initiatives aimed at expanding drug coverage is expected to drive growth of the market. For instance, in 2018, the Ministry of Health and Long-Term Care of Ontario announced that all patients are eligible for Ontario Drug Benefit (ODP) irrespective of severity of their disease. In the same year, Thunder Bay group, a company that provides HIV/AIDS/Hepatitis C education and support services, expand its presence into medicines, as a result of successful negotiations between provinces and drug manufacturers. It is an integrated initiative for the prevention and control of viral hepatitis in India to achieve Sustainable Development Goal (SDG), which aims to end viral hepatitis by 2030. Browse Research Reports: https://www.coherentmarketinsights.com/market- insight/hepatitis-drugs-market-2977 © Coherent market Insights. All Rights Reserved

3. REPORT DESCRIPTION Moreover, availability of Hepatitis C drugs is expected to increase over the forecast period due to increasing drug development. Growth of the hepatitis drugs market is being driven by direct acting antivirals (DAAs), which aid the development of highly effective, INF-free hepatitis C drugs. The product pipeline of market players consists of dual as well as triple DDA combinational therapies against the hepatitis C virus. A combination of drugs is more effective for the treatment of hepatitis C as compared to single regimen. For instance, in 2016, Gilead submitted a new drug application of a fixed-dose combination SOF/VEL/voxilaprevir for treatment of HCV genotypes 1–6 to the U.S. FDA. Moreover, in January 2017, drug assessment of the SOF/VEL/voxilaprevir combination was granted by the European Medicines Agency (EMA) Browse 38 Market Data Tables and 27 Figures spread through 173 Pages and in-depth TOC on "Hepatitis Drugs Market, By Drug Class (Interferon Alphas, HIV NRTIs, Nucleotide Polymerase/NS5A Inhibitor Combinations, Hepatitis C Protease/NS5A Inhibitor Combinations, NS5A Inhibitors, Nucleotide Polymerase Inhibitors, Nucleoside Analogue Antivirals and Thrombopoiesis Stimulating Agents), By Disease Type (Hepatitis B, Hepatitis C and Others), By Route of Administration (Oral and injection), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026" Request a Sample copy of this reports: https://www.coherentmarketinsights.com/insight/request-sample/2977 © Coherent market Insights. All Rights Reserved

4. REPORT DESCRIPTION Additionally, on 28th July 2018 (World Hepatitis Day) the National Viral Hepatitis Control Program was launched by the Ministry of Health and Family Welfare, Government of India. Key Takeaways of the Hepatitis Drugs Market: The global hepatitis drugs market is expected to expand at a CAGR of 3.2% during the forecast period (2019–2027), owing to increasing government initiatives and drug development for hepatitis treatment. Among disease type, Hepatitis B is expected to hold major revenue share in 2026, owing to increasing global prevalence of hepatitis B. For instance, according to world health organization (WHO) estimates, in 2015, 257 million people were living with chronic hepatitis B infection, and 8, 87, 000 deaths occurred due to hepatitis B globally. Major players operating in the global hepatitis drugs market include Merck & Co. Inc., Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, GlaxoSmithKline PLC., and Cipla Inc. Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2977 © Coherent market Insights. All Rights Reserved

5. ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. SERVICES CUSTOMIZED RESEARCH INDUSTRY ANALYSIS SYNDICATED RESEARCH COUNTRY SPECIFIC STUDIES MARKET INTELLIGENCE SERVICES CONSULT STUDIES © Coherent market Insights. All Rights Reserved

6. ABOUT CMI SECTOR COVERAGE BIOTECHNOLOGY CLINICAL DIAGNOSTIC HEALTHCARE IT MEDICAL DEVICES MEDICAL IMAGING PHARMACEUTICAL OUR CLIENTS  Global Leading Equipment and System Manufacturers  Marketing Consultancies and the Advertising Industry  Component Providers and System Integrators  Private and Government organization  Distributors, Retailors and Value Added Resellers  Outsourcing Companies  Healthcare IT Solutions Developers  Universities and Business Schools. © Coherent market Insights. All Rights Reserved

7. KEY STATS RESEARCH SOLUTIONS 100+ GLOBAL REPORTS FEASIBILITY STUDIES Insights Published Per Year CUSTOMIZED SOLUTIONS 150+ COUNTRY ANALYSIS Consulting Projects Till Date CONSULT PROJECTS SURVEY RESEARCH 125+ EXCEL FORECAST DATABASE Clients Worldwide Per Year COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS 110+ Analysts and Contract Consultants Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved

8. THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702 © Coherent market Insights. All Rights Reserved